• Update of our Target 96 Development panel (Oct 2020)

    In response to customer feedback and as part of Olink’s commitment to improve and develop our offering, a change has been made to the Olink®Target 96 Development panel. A high performance assay with a possible role in bone remodeling, metabolic diseases and tumorigenesis has been selected from our customer driven wish-list. This has been incorporated into an updated version of the panel, replacing one assay from the previous version. For more details please visit the panel update page.